Drug profile · INN
gemcitabine
DBL GEMCITABINE INJECTION
gemcitabine (DBL GEMCITABINE INJECTION) is a dna polymerase (alpha/delta/epsilon) inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — gemcitabine
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 20
- Programs
- 137
- Data quality
- 0.89
Quick answer
gemcitabine (DBL GEMCITABINE INJECTION) is a dna polymerase (alpha/delta/epsilon) inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA polymerase (alpha/delta/epsilon) inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Congress & event coverage
- PresentationScopeX
Pipeline programs
Related patents
-
US 12377112
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
granted -
US 12338438
Conjugated oligonucleotide compounds, methods of making and uses thereof
granted -
US 12145943
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 12116374
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11970538
Multispecific binding constructs against checkpoint molecules and uses thereof
granted -
US 11865126
Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
granted -
US 11738035
Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
granted -
US 11661617
Processes for the production of tryptamines
granted -
US 11564935
Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
granted -
US 11407759
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11136334
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11046769
Multispecific binding constructs against checkpoint molecules and uses thereof
granted -
US 10973869
Methods of treating cardiomyopathy associated with genetic disorders
granted -
US 10961238
Modulators of hedgehog (Hh) signaling pathway
granted -
US 10532059
Steroid hormone pharmaceutical composition
granted -
US 10369098
Methods for localized drug delivery
granted -
US 10286077
Steroid hormone compositions in medium chain oils
granted -
US 10098894
Transdermal cream
granted -
US 9974853
Immunoregulatory peptides and methods of use
granted -
US 9931349
Steroid hormone pharmaceutical composition
granted
Frequently asked questions
What is gemcitabine?
gemcitabine (DBL GEMCITABINE INJECTION) is a dna polymerase (alpha/delta/epsilon) inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for gemcitabine?
DBL GEMCITABINE INJECTION is a marketed brand name for gemcitabine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of gemcitabine?
gemcitabine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.